HEALTH · May 8, 2026 Pfizer Inc. listed hantavirus pulmonary syndrome as a potential adverse event of special interest (AESI) or possible side effect in its COVID-19 vaccine safety monitoring documents for the BNT162b2 (Comirnaty) vaccine. HARDLY BS
HEALTH · May 7, 2026 As of May 7, 2026, the case-fatality rate of Hantavirus Pulmonary Syndrome in the United States is about 35%. HARDLY BS